Association between Copeptin and Metabolic Syndrome: A Systematic Review

Background. Copeptin, a reliable marker for vasopressin release, has been associated with cardiometabolic diseases including metabolic syndrome (MetS). This systematic review aims to evaluate the association between copeptin and MetS. Methods. We searched in Pubmed, Scopus, EMBASE, and Web of Scienc...

Full description

Saved in:
Bibliographic Details
Main Authors: Ricardo Rojas-Humpire, David R. Soriano-Moreno, Brenda Galindo-Yllu, Jessica Hanae Zafra-Tanaka
Format: Article
Language:English
Published: Wiley 2022-01-01
Series:Journal of Nutrition and Metabolism
Online Access:http://dx.doi.org/10.1155/2022/5237903
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849412555920900096
author Ricardo Rojas-Humpire
David R. Soriano-Moreno
Brenda Galindo-Yllu
Jessica Hanae Zafra-Tanaka
author_facet Ricardo Rojas-Humpire
David R. Soriano-Moreno
Brenda Galindo-Yllu
Jessica Hanae Zafra-Tanaka
author_sort Ricardo Rojas-Humpire
collection DOAJ
description Background. Copeptin, a reliable marker for vasopressin release, has been associated with cardiometabolic diseases including metabolic syndrome (MetS). This systematic review aims to evaluate the association between copeptin and MetS. Methods. We searched in Pubmed, Scopus, EMBASE, and Web of Science databases until March 2021 and included observational studies (cohort studies, cross-sectional, and case-control) reporting the risk or prevalence of having MetS in patients with elevated copeptin levels compared to patients without elevated copeptin levels. The risk of bias was evaluated with the Newcastle-Ottawa Scale. Meta-analysis was not performed because of the heterogeneity of the copeptin cut-off values. Results. A total of 7 studies (5 cross-sectional, 1 case-control, and 1 cohort) were included comprising 11,699 participants. Most of them were performed in the adult general population. Two cross-sectional and one case-control studies found a positive significant association between higher levels of copeptin and MetS. While three cross-sectional and one cohort studies found no association. The case-control study had several methodological limitations, most cross-sectional studies were methodologically adequate and the cohort study had no methodological issues. Conclusions. The association between copeptin and MetS is inconsistent. However, the arginine-vasopressin system impairment contributes to metabolic disorders, expressing plasma copeptin changes. Thus, more longitudinal studies are required to corroborate the association of copeptin and MetS.
format Article
id doaj-art-6463e39dc0c8455f9730d5a1710c79ef
institution Kabale University
issn 2090-0732
language English
publishDate 2022-01-01
publisher Wiley
record_format Article
series Journal of Nutrition and Metabolism
spelling doaj-art-6463e39dc0c8455f9730d5a1710c79ef2025-08-20T03:34:25ZengWileyJournal of Nutrition and Metabolism2090-07322022-01-01202210.1155/2022/5237903Association between Copeptin and Metabolic Syndrome: A Systematic ReviewRicardo Rojas-Humpire0David R. Soriano-Moreno1Brenda Galindo-Yllu2Jessica Hanae Zafra-Tanaka3Unidad de Investigación Clínica y EpidemiológicaUnidad de Investigación Clínica y EpidemiológicaUnidad de Investigación Clínica y EpidemiológicaEscuela de MedicinaBackground. Copeptin, a reliable marker for vasopressin release, has been associated with cardiometabolic diseases including metabolic syndrome (MetS). This systematic review aims to evaluate the association between copeptin and MetS. Methods. We searched in Pubmed, Scopus, EMBASE, and Web of Science databases until March 2021 and included observational studies (cohort studies, cross-sectional, and case-control) reporting the risk or prevalence of having MetS in patients with elevated copeptin levels compared to patients without elevated copeptin levels. The risk of bias was evaluated with the Newcastle-Ottawa Scale. Meta-analysis was not performed because of the heterogeneity of the copeptin cut-off values. Results. A total of 7 studies (5 cross-sectional, 1 case-control, and 1 cohort) were included comprising 11,699 participants. Most of them were performed in the adult general population. Two cross-sectional and one case-control studies found a positive significant association between higher levels of copeptin and MetS. While three cross-sectional and one cohort studies found no association. The case-control study had several methodological limitations, most cross-sectional studies were methodologically adequate and the cohort study had no methodological issues. Conclusions. The association between copeptin and MetS is inconsistent. However, the arginine-vasopressin system impairment contributes to metabolic disorders, expressing plasma copeptin changes. Thus, more longitudinal studies are required to corroborate the association of copeptin and MetS.http://dx.doi.org/10.1155/2022/5237903
spellingShingle Ricardo Rojas-Humpire
David R. Soriano-Moreno
Brenda Galindo-Yllu
Jessica Hanae Zafra-Tanaka
Association between Copeptin and Metabolic Syndrome: A Systematic Review
Journal of Nutrition and Metabolism
title Association between Copeptin and Metabolic Syndrome: A Systematic Review
title_full Association between Copeptin and Metabolic Syndrome: A Systematic Review
title_fullStr Association between Copeptin and Metabolic Syndrome: A Systematic Review
title_full_unstemmed Association between Copeptin and Metabolic Syndrome: A Systematic Review
title_short Association between Copeptin and Metabolic Syndrome: A Systematic Review
title_sort association between copeptin and metabolic syndrome a systematic review
url http://dx.doi.org/10.1155/2022/5237903
work_keys_str_mv AT ricardorojashumpire associationbetweencopeptinandmetabolicsyndromeasystematicreview
AT davidrsorianomoreno associationbetweencopeptinandmetabolicsyndromeasystematicreview
AT brendagalindoyllu associationbetweencopeptinandmetabolicsyndromeasystematicreview
AT jessicahanaezafratanaka associationbetweencopeptinandmetabolicsyndromeasystematicreview